Newswire (Published: Friday, January 20, 2017, Received: Friday, January 13, 2017, 12:18:44 AM CST)
Word Count: 377
By a News Reporter-Staff News Editor at Drug Week -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting originating from Baltimore, Maryland, by NewsRx correspondents, research stated, "The treatment landscape for patients with metastatic castration-resistant prostate cancer (CRPC) is evolving, with recent approvals of immune therapy, novel hormonal therapy, and bone-targeted therapy. Chemotherapy remains an essential component of the armamentarium."
Our news editors obtained a quote from the research from Johns Hopkins University, "Herein, we review current chemotherapy options for patients with CRPC and discuss future challenges. We reviewed literature for chemotherapy agents in prostate cancer, with special attention to the evidence for efficacy of the currently approved agents. We also reviewed emerging data on biomarkers of response to chemotherapy for CRPC. Taxanes, especially docetaxel and cabazitaxel, have first-and second-line indications for CRPC, respectively, with both providing a survival benefit. Multiple attempts to improve on the single agent efficacy of docetaxel with combination therapy have not generally been successful although platinum combinations are used for resistant phenotypes. Reductions in prostate-specific antigen by greater than or equal to30% and reductions in circulating tumor cells (CTCs) to less than or equal to 5 are associated with improved survival on chemotherapy. Chemotherapy may continue to be effective therapy for patients with biomarkers that are associated with resistance to androgen-directed therapies (androgen receptor splice variant 7 positivity in CTCs or high CTC heterogeneity)."
According to the news editors, the research concluded: "Chemotherapy remains an essential component of CRPC therapy, and biomarkers are being identified to define clinical scenarios where chemotherapy may be the optimal therapy choice."
For more information on this research see: Chemotherapy options in castration-resistant prostate cancer. Indian Journal of Urology, 2016;32(4):262-270 (see also Oncology - Prostate Cancer).
The news editors report that additional information may be obtained by contacting B.A. Teply, Dept. of Oncology, Johns Hopkins University, Baltimore, Maryland, United States.
Keywords for this news article include: Maryland, Oncology, Baltimore, Chemotherapy, United States, Article Review, Prostate Cancer, Drugs and Therapies, Prostatic Neoplasms, North and Central America, Diagnostics and Screening.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Johns Hopkins University
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Treatments and Therapies